ArticleJMIR medical informatics2024
Design and Implementation of a Dashboard for Drug Interactions Mediated by Cytochromes Using a Health Care Data Warehouse in a University Hospital Center: Development Study.
Article in JMIR medical informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The enzymatic system of cytochrome P450 (CYP450) is a group of enzymes involved in the metabolism of drugs present in the liver. Literature records instances of underdosing of drugs due to the concurrent administration of another drug that strongly induces the same cytochrome for which the first drug is a substrate and overdosing due to strong inhibition. IT solutions have been proposed to raise awareness among prescribers to mitigate these interactions. Objective: This study aimed to develop a drug interaction dashboard for Cytochrome-mediated drug interactions (DIDC) using a health care data warehouse to display results that are easily readable and interpretable by clinical experts. Methods: The initial step involved defining requirements with expert pharmacologists. An existing model of interactions involving the (CYP450) was used. A program for the automatic detection of cytochrome-mediated drug interactions (DI) was developed. Finally, the development and visualization of the DIDC were carried out by an IT engineer. An evaluation of the tool was carried out. Results: The development of the DIDC was successfully completed. It automatically compiled cytochrome-mediated DIs in a comprehensive table and provided a dedicated dashboard for each potential DI. The most frequent interaction involved paracetamol and carbamazepine with CYP450 3A4 (n=50 patients). The prescription of tacrolimus with CYP3A5 genotyping pertained to 675 patients. Two experts qualitatively evaluated the tool, resulting in overall satisfaction scores of 6 and 5 out of 7, respectively. Conclusions: At our hospital, measurements of molecules that could have altered concentrations due to cytochrome-mediated DIs are not systematic. These DIs can lead to serious clinical consequences. The purpose of this DIDC is to provide an overall view and raise awareness among prescribers about the importance of measuring concentrations of specific drugs and metabolites. Ultimately, the tool could lead to an individualized approach and become a prescription support tool if integrated into prescription assistance software.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.